Enzyme Catalysis

As a CRO that advocates green drug research and development, Medicilon has always been committed to promoting the green upgrading of pharmaceutical processes through technological innovation. Medicilon has already used enzymes in process research and development, and relying on its strong chemical and biological background, Medicilon has established a the Enzyme Catalysis Technology Platform to screen catalytic enzymes for specific reaction types and establish corresponding enzyme libraries to assist process development and production.

Medicilon Enzyme Catalysis Service Platform

01 Chemical Technology Platform
Development of Pharmaceutical Intermediates and APls
Functional Chemical Development
02 Biotechnology Platform
Enzyme Development and Applications
Enzyme Production
03 Quality Technology Platform
Quality and Control Research
Inspection and Testing Services
Medicilon's Enzyme Catalysis Technology Platform includes chemical technology platform, biotechnology platform, and quality technology platform. The platform focuses on the combination of chemical synthesis and biological enzyme catalytic synthesis, the development and application research of biological enzymes, and the R&D and production of pharmaceutical intermediates and APIs using green biotechnology. At the same time, it provides high-end CRO, CDMO services, testing and quality research services to pharmaceutical companies.

Medicilon Enzyme Library

/d/image/20230920/650a7f843c54d.webp

Ketoreductase	D-amino acid dehydrogenase	Transaminase	Nitrile Hydratase	Phenylalanine Lyase	Hydroaminase
Cytochrome Monooxygenase	Threonine Dehydrogenase	Phosphokinase	Epoxide Hydrolase		Nitrilase
Alcohol Oxidase	Formate Dehydrogenase	Nucleoside Phosphorylation (synthesis)	Amidohydrolase		Aldol Condensase
Monoamine Oxidase	Glucose Dehydrogenase		Nitrilase		Other Specialized Enzymes
Nitrile	Lactate			Lactate
Reductase	Dehydrogenase			Dehydrogenase
Nitroreductase	Phenylalanine Dehydrogenase
Imine Reductase	Ammonia Dehydrogenase

At present, Medicilon has successfully established dozens of major biological enzyme libraries, such as ketoreductase, ester hydrolase, imine reductase, nitroreductase, cyclooxygenase, amide hydrolase, for providing suitable biocatalytic solutions for various chemical transformations. These integrated enzymatic services reduce costs, shorten time, and improve quality. With the implementation of a large amount of projects, Medicilon enzyme library is also continuing to be optimized and expanded. Medicilon will also carry out research on immobilized enzymes and coenzymes.

Medicilon’s R&D capabilities in the field of synthetic biology

With the continuous advancement of synthetic biology technology, more and more enzymes with specific catalytic functions are used as biocatalysts to achieve reactions that are difficult to achieve with chemical catalysts, and can be used as catalytic components to build functional modules of synthetic biology. Medicilon has already established a presence in the field of synthetic biology. Through the assembly of different enzyme components, Medicilon has made breakthroughs in the design of synthetic routes for many target molecules and can provide a variety of services:
Molecule and Strain ConstructionStrain Delection and DomesticationEnzyme Co-ExpressionMulti-Enzyme CatalysisBiocatalysisProtein ModificationFermentation MetabolismProtein PurificationFermentation OptimizationEnzyme Immobilization
In the future, Medicilon, as a one-stop biopharmaceutical preclinical R&D service platform, will continue to explore and apply more innovative green chemical technologies to achieve more environmentally friendly, safe, efficient and economical process development and production, and create more innovative products for global clients.

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Shanghai Medicilon Inc.

搜索此博客